Bavencio

Chemical Nameavelumab
Dosage FormInjection (intravenous; 200 mg/10 ml)
Drug ClassMonoclonal antibodies
SystemSkin, Urinary
CompanyEMD Serono, Inc.
Approval Year2017

Indication

  • To treat metastatic Merkel cell carcinoma in patients ≥ 12 years of age.
  • To treat locally advanced or metastatic urothelial carcinoma in patients with disease progression during or following platinum-containing chemotherapy and who have had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
  • To treat advanced renal cell carcinoma as a first line treatment in conjunction with axitinib.
Last updated on 11/6/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Bavencio (Avelumab) Prescribing Information 2017EMD Serono, Inc., Rockland, MA
Document TitleYearSource
SEOM clinical guideline for treatment of kidney cancer (2019). 2020Clinical and Translational Oncology
Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. 2017Journal of the National Comprehensive Cancer Network